← Back to Search

Physical Therapy

Hybrid Physical Therapy for Osteoarthritis (RAPTOR Trial)

N/A
Recruiting
Led By Allyn Bove, DPT, PhD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant meets American College of Rheumatology criteria for the clinical diagnosis of knee osteoarthritis
Participant is aged 40 or over
Must not have
Chronic neurological disorder affecting balance or coordination
Any other disorder that affects balance or gait
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, which is anticipated to take approximately 1 year.
Awards & highlights

Summary

This trial is testing a new way to provide rehabilitation for people with knee pain, using a combination of in-person and remote (telerehabilitation) interventions. The goal is to see if this is feasible and effective.

Who is the study for?
This trial is for rural adults over 40 in western Pennsylvania with knee osteoarthritis, who can visit a clinic twice and have internet plus a device for telehealth. It's not for those with balance/gait disorders, multiple recent falls, or chronic neurological issues affecting coordination.Check my eligibility
What is being tested?
The RAPTOR program combines in-person and telehealth physical therapy to see if it's feasible and safe for treating knee osteoarthritis pain and improving function and quality of life in rural patients.See study design
What are the potential side effects?
Since the intervention involves physical therapy exercises, potential side effects may include muscle soreness or strain. However, as this is non-invasive treatment, serious side effects are unlikely.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with knee osteoarthritis.
Select...
I am 40 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a long-term nerve condition that affects my balance or coordination.
Select...
I have a condition that affects my walking or balance.
Select...
I have fallen at least twice in the past year or sought medical help for a fall.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, which is anticipated to take approximately 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, which is anticipated to take approximately 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinically Important Improvement on ONE Functional Outcome Measure
Recruitment Target
Study-Related Adverse Events / Serious Adverse Events
+2 more
Secondary outcome measures
Functional outcome measure: 30-second chair stand test
Functional outcome measure: 40-meter fast-paced walk test
Functional outcome measure: 6-minute walk
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: RAPTOR Physical Therapy InterventionExperimental Treatment1 Intervention
RAPTOR intervention: hybrid in-person + telehealth physical therapy care for rural-dwelling individuals with knee osteoarthritis

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,737 Previous Clinical Trials
16,339,230 Total Patients Enrolled
12 Trials studying Osteoarthritis
4,758 Patients Enrolled for Osteoarthritis
University of Pittsburgh Medical Center Rehabilitation InstituteUNKNOWN
Allyn Bove, DPT, PhDPrincipal InvestigatorUniversity of Pittsburgh

Media Library

RAPTOR protocol (Physical Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05114512 — N/A
Osteoarthritis Research Study Groups: RAPTOR Physical Therapy Intervention
Osteoarthritis Clinical Trial 2023: RAPTOR protocol Highlights & Side Effects. Trial Name: NCT05114512 — N/A
RAPTOR protocol (Physical Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05114512 — N/A
~8 spots leftby Jul 2025